{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:42:36Z","timestamp":1758346956843,"version":"3.44.0"},"reference-count":12,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Valproic acid is a known teratogen. The aim was to identify contraceptive use in a group of women using valproic acid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Descriptive study. A total of 22\u2009855 women of childbearing age (15\u201349\u2009years) with at least 1 month of valproic acid use from January 2022 to December 2023 were selected from a Colombian drug\u2010dispensing database. Data on the dispensing of hormonal contraceptives were searched during the study period. The time and rate of coverage (% of the period during which women took contraceptives while using valproic acid\/total period of valproic acid consumption) with contraceptives were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the women included, 71.4% (<jats:italic>n<\/jats:italic>\u2009=\u200916\u2009308) used 250\u2010mg valproic acid tablets. The mean age was 32.7 (standard deviation [SD]: 9.9) years, and the most common related diagnosis was migraine and headache (<jats:italic>n<\/jats:italic>\u2009=\u20095163, 22.6%). Only 8.0% (<jats:italic>n<\/jats:italic>\u2009=\u20091832) of the women had at least 1 day of coverage with some contraceptive while using valproate. For the patients with at least 1 day of coverage, the average duration of coverage was 72.5 (SD: 84.7) days (median: 30\u2009days; IQR: 30\u201386\u2009days). This represents an overall coverage rate of 5.3% (SD: 20.4%) (median: 0.0) and a coverage rate of 65.7% (SD: 35.1%) (median: 75.8%, IQR: 33.3\u2013100%) for those with at least 1 day of coverage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A significant proportion of women of childbearing age are likely at risk of becoming pregnant while taking valproic acid.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.70208","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:20:22Z","timestamp":1755066022000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Valproic Acid Among Women of Childbearing Age and Its Concomitant Use With Contraceptives in Colombia"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge E.","family":"Machado\u2010Alba","sequence":"first","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia Universidad Tecnol\u00f3gica de Pereira\u2010Audifarma S.A  Pereira, Risaralda Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-7658","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Gaviria\u2010Mendoza","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia Universidad Tecnol\u00f3gica de Pereira\u2010Audifarma S.A  Pereira, Risaralda Colombia"},{"name":"Grupo de Investigaci\u00f3n Biomedicina, Facultad de Medicina Fundaci\u00f3n Universitaria Aut\u00f3noma de Las Am\u00e9ricas  Pereira Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-0986","authenticated-orcid":false,"given":"Manuel E.","family":"Machado\u2010Duque","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia Universidad Tecnol\u00f3gica de Pereira\u2010Audifarma S.A  Pereira, Risaralda Colombia"},{"name":"Grupo de Investigaci\u00f3n Biomedicina, Facultad de Medicina Fundaci\u00f3n Universitaria Aut\u00f3noma de Las Am\u00e9ricas  Pereira Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-0101","authenticated-orcid":false,"given":"Luis F.","family":"Valladales\u2010Restrepo","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia Universidad Tecnol\u00f3gica de Pereira\u2010Audifarma S.A  Pereira, Risaralda Colombia"},{"name":"Grupo de Investigaci\u00f3n Biomedicina, Facultad de Medicina Fundaci\u00f3n Universitaria Aut\u00f3noma de Las Am\u00e9ricas  Pereira Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2013","authenticated-orcid":false,"given":"Albert","family":"Figueras","sequence":"additional","affiliation":[{"name":"Independent Consultant on safe and Appropriate Use of Medicines Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010390"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2014.09.005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.14482\/sun.39.01.124.566"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.661"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5490"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/aur.2696"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/17549507.2013.866271"},{"volume-title":"Bolet\u00edn epidemiol\u00f3gico semanal [Weekly Epidemiological Bulletin, Week 7, 2022]","year":"2022","author":"Instituto Nacional de Salud","key":"e_1_2_8_9_1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.33610\/01229907.2021v3n3a2"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00381\u2010023\u201005910\u20107"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.12680"},{"volume-title":"Encuesta Nacional de Demograf\u00eda y Salud\u2014ENDS 2015. Tomo II: Componente de Salud Sexual y Salud Reproductiva","year":"2018","author":"Asociaci\u00f3n Profamilia, Ministerio de Salud y Protecci\u00f3n Social","key":"e_1_2_8_13_1"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:41:57Z","timestamp":1758256917000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/pds.70208"],"URL":"https:\/\/doi.org\/10.1002\/pds.70208","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2024-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70208"}}